Dr Torill Bigg, Chief Carbon Reduction Scientist, Tunley Environmental explores scope 3 and how it can be the largest part by far of an organisation’s carbon footprint, and not all of them can justly be laid at the foot of the supply chain.
Regulatory authorities have been focusing on safeguarding global supply chains. Juan Torrijos Lopez, GMP consultant at Rephine provides some practical pointers as to how pharmaceutical manufacturers should respond to evolving expectations.
Rex Clements, CEO at Centrient Pharmaceuticals, sheds light on the company’s efforts to contribute to a more sustainable global supply chain for antibiotics.
EPM spoke with Nick Porter and Simon Brinckmann, World Courier, about its investment in a real-time location monitoring solution, the unique logistics considerations posed by ATMPs, and World Courier’s expanding geographic footprint.
Cem Zorlular, CEO of Er-Kim Pharmaceuticals, shares his insights on how pharma manufacturers can better navigate the global commercialisation of treatments in an ever-changing landscape.
Kevin Doran, global head of supply chain at Tower Cold Chain, discusses the role and growing importance of last-mile delivery in the pharmaceutical cold chain.
Nick Porter, World Courier, and Chris Williams, Alloga Europe, discuss the heightened demand for cold chain and cryogenic storage to support advanced therapy medicinal products (ATMPs) and the solutions needed to safeguard the supply chain.
Lee Feander, senior director with Alvarez & Marsal Healthcare and Life Sciences practice, explores the three areas that pharmaceutical companies need to address to better tackle the current UK drug shortage.
